The short answer
Testicular cancer treatment turns on three things: seminoma versus nonseminoma, the AFP, beta-hCG and LDH levels drawn before and after orchiectomy, and what the abdominal CT shows. Cure rates exceed 90% for seminoma overall and approach 100% at low stage. These are the questions that pin those details down.
AFP, beta-hCG and LDH must be drawn before the testicle is removed, because the drop afterward carries prognostic weight.
Any raised AFP means the tumor is managed as a nonseminoma, even when the pathology reads pure seminoma, because seminomas do not make AFP.
Removal is done through the groin, not the scrotum: a review found local recurrence of 2.9% with the scrotal approach versus 0.4% with the inguinal approach.
For stage I seminoma, surveillance, adjuvant carboplatin, and radiation all reach a cure rate near 100%, and radiation is no longer favored because of second cancers.
Choose how you want to understand this
The full explanation.
What actually drives the plan
Three things set the direction, and all three are usually settled in the first two weeks.
The first is histology: seminoma or nonseminoma. Any tumor that is 100% seminoma is a seminoma. Everything else, including any mixture, is managed as a nonseminoma.
The second is the tumor markers, drawn before and after the testicle comes out.
The third is what the abdominal CT shows in the retroperitoneal lymph nodes.
The context is worth stating plainly. NCI calls testicular cancer highly treatable and usually curable. For seminomas across all stages, the cure rate is over 90%. For low-stage seminomas or nonseminomas, it nears 100%. For 2026 the count of new US cases is put at 9,810, with 630 deaths — an American Cancer Society forecast that NCI passes on.
The markers, and why timing matters
AFP, beta-hCG, and LDH should be measured before the testicle is removed. That is a clear instruction in NCI's clinical summary. It is easy to miss in a fast-moving week.
Here is what each one does:
- AFP is raised in 40% to 60% of men with nonseminomas. Seminomas do not make it. So a raised AFP means a mixed germ cell tumor, even when the pathology reads pure seminoma. The exception is a better explanation, such as liver disease.
- Beta-hCG is raised in about 14% of stage I pure seminomas before surgery, in about half of metastatic seminomas, and in 40% to 60% of nonseminomas.
- LDH rises in both types. NCI is candid that it is weak on its own. One study covered 499 patients. A raised LDH was unrelated to cancer in 7.7%, and cancer-related in only 1.4%. The positive predictive value was 12.8%.
Two false-positive traps are worth naming. Beta-hCG assays can cross-react with luteinizing hormone, which is one reason a mildly raised result on its own does not settle anything. There are also clinical reports of marijuana use raising beta-hCG. Either way, a marker that does not fit the rest of the picture is confirmed by the treating team, using repeat testing and whichever additional assay they judge appropriate, before it is allowed to change the plan.
Questions about the surgery
- Will this be a radical inguinal orchiectomy, through the groin, with high tying of the spermatic cord?
- Why is a cut through the scrotum avoided?
That second question has a number attached. A review of published series compared the two routes. Local recurrence was 2.9% through the scrotum and 0.4% through the groin. Distant recurrence and survival were the same. The local gap was statistically significant. The worry is spilling tumor into scrotal tissue or groin nodes.
- Can sperm banking happen before the operation, or is between surgery and chemotherapy soon enough?
- Is a testicular implant an option, and can it go in during the same operation?
Questions about stage I seminoma
This is where the choice is genuinely open, and where a clear conversation pays off most.
Surveillance after surgery means no radiation and no chemotherapy. Scans take their place. NCI describes the schedule used in the reported series, which ran scans and chest imaging frequently in the first years and then tapered over roughly a decade. Do not treat that as your timetable. Current surveillance protocols are risk-adapted and deliberately restrained about CT, because the radiation from repeated scanning carries its own long-term cost, and MRI is increasingly used in its place. Ask your centre for its own written, dated surveillance schedule and what each appointment involves.
More than 1,200 patients have been managed this way. The 10-year recurrence rate was 15% to 20%. Nearly all recurrences were cured with later radiation or chemotherapy. Relapse after 5 years is unusual, but it happens in up to 4%.
Two features change the odds:
- Tumor larger than 4 cm.
- Invasion of the rete testis.
The 5-year relapse risk in the series NCI reports was about 10% with neither, 16% with one, and 32% with both. They shift the odds; they do not by themselves decide between surveillance and treatment, and not every guideline weighs them the same way. Ask for the numbers by name, then ask what your team recommends and why.
If surveillance does not appeal, a short course of carboplatin is the main alternative. The MRC-TE19 trial randomized 1,477 men to carboplatin or to radiation; the carboplatin dose is calculated individually from kidney function by the oncology team. Five-year relapse-free survival was 94.7% and 96.0%, a gap of 1.3%. The single seminoma death was in the radiation arm.
Radiation is no longer favored. The reason is second cancers. A SEER analysis covered 7,179 men treated with radiation for stage I seminoma. It found a raised risk of death from second cancers, with a standardized mortality ratio of 1.89. An international study followed survivors for 20 to 29 years. Radiation doubled the risk of a second cancer.
Questions about stage I nonseminoma
Ask what the pathology says about lymphovascular invasion and the proportion of embryonal carcinoma. Both push toward treatment rather than surveillance.
Ask about the CT too. Some patients have normal scans and normal markers after surgery. NCI reports that nearly 20% with seminoma and 30% with nonseminoma still relapse if nothing more is done. A clean scan is not the same as no disease.
If retroperitoneal lymph node dissection comes up, ask whether a nerve-sparing technique is planned, because the nerves involved control ejaculation.
Where to get a second opinion, and why
Volume matters here, and it is measurable. One analysis covered 380 patients on the same protocol at 49 institutions, across two European trial groups. Outcomes differed by institution. Ask whether a tumor board will review the case. Ask how often the center treats germ cell tumors.
One more question is worth asking. Does trial eligibility depend on a start date? Some options close once first-line therapy begins.
What to write down before the visit
Bring the pathology report, the marker values with their dates, and the CT report. Ask for the numbers, not a summary word. Tumor size in centimeters and the exact marker values are what the decision rests on.
Our page on testicular cancer covers the basics, and our page on metastatic testicular cancer covers the questions that come up if disease has spread.
Sources
- National Cancer Institute, Testicular Cancer Treatment (PDQ) - Health Professional Version, updated May 16, 2025, accessed August 6, 2026
- National Cancer Institute, Testicular Cancer Treatment (PDQ) - Patient Version, accessed August 6, 2026
- American Cancer Society — Cancer Facts & Figures
Words to know
Tap any term to see what it means.
Common questions
Why does the surgery go through the groin instead of the scrotum?
To avoid seeding tumor into scrotal tissue or inguinal lymph nodes. NCI reports that a retrospective analysis of published series found local recurrence in 2.9% of transscrotal approaches versus 0.4% of inguinal approaches. Distant recurrence and survival were the same.
Why do the tumor markers have to be drawn before surgery?
Because the pattern before and after removal is what carries meaning. For nonseminomas, NCI describes the degree of marker elevation after the testicle is removed as one of the most significant predictors of prognosis.
What if the pathology says seminoma but AFP is raised?
It is managed as a nonseminoma. Seminomas do not produce AFP, so a raised level means a mixed germ cell tumor, unless there is a stronger explanation such as liver disease.
Is stage I seminoma always treated after surgery?
No. Surveillance is a standard option, with a 10-year recurrence rate of 15% to 20% and nearly all recurrences cured by later treatment. Radiation reaches similar cure rates but is no longer favored, because a SEER analysis of 7,179 men found a raised risk of death from second cancers.
Questions to ask your doctor
Being prepared helps you get the most out of your appointments. Save or print these questions.
Tap a question to save it to your list (kept on this device).
Your next step
Turn this topic into questions for your next appointment.
Speak With Trained Specialists & Human Navigators
Cancer Explained provides educational guidance, but does not replace trained specialists, social workers, or your medical team.
Talk to a trained cancer information specialist
Free, confidential assistance from NCI Cancer Information Service via phone, chat, or email.
Contact your oncology team
Locate after-hours contact numbers, portal messages, or urgent triage phone lines.
Find a patient navigator
Get one-on-one help with appointments, logistics, translation, and care coordination.
Find a genetic counselor
Discuss inherited mutation risk, family history, and genetic testing options.
Find an oncology social worker
Access emotional counseling, family support groups, and mental health resources.
Find a financial navigator
Locate copay assistance foundations, grant programs, and lodging/travel support.
Find a clinical-trial specialist
Search matching studies and speak with NCI trial information specialists.
Get urgent help
Immediate emergency guidance for fever (>100.4°F during chemo), severe pain, or shortness of breath.
Help Us Improve This Guide
Did this explanation answer your question and help you determine your next step?
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Plain-language explanation of the published sources cited on this page. AI-assisted, source-checked, not clinician-reviewed.
Sources last checked: 2026-08-16 what this meansLast updated: 2026-08-19Next planned review: 2027-07-30
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status — Source checked. This page was written with AI assistance and checked line by line against the sources listed on it. That confirms the sources support what the page says. It is not a medical review, and it does not confirm the page is complete or right for your situation.
General education — varies by person. Answers genuinely differ between people. This page explains what commonly varies and points you to your care team for your situation.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status: Source checked — This page was written with AI assistance and checked line by line against the sources listed on it. That confirms the sources support what the page says. It is not a medical review, and it does not confirm the page is complete or right for your situation.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
Read more about our editorial process, our use of AI, and our corrections policy.
Spotted a problem? Report an error — a factual mistake, broken or outdated source, confusing wording, or anything that seems unsafe. Please do not include names, medical record numbers, dates of birth, addresses, or other identifying medical information in your report.
After using this page, do you understand what to do next?
Anonymous — we only record the answer, never who gave it.
Related articles
Still have questions?
Educational answers, plain language
Free to print and share